NLRP3 and allergic asthma: demonstrated that OLT1177 could inhibit NLRP3 and caspase-1 activity, reduce the release of pro-inflammatory IL-1β, and ameliorate pathophysiological indicators in three experimental mouse models of allergic asthma (127).